Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy
about
B-Raf and the inhibitors: from bench to bedsideCirculating biomarkers to monitor cancer progression and treatmentCell-free circulating tumor DNA in cancercfDNA analysis from blood in melanomaImpact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing researchLiquid biopsies: genotyping circulating tumor DNACirculating serologic and molecular biomarkers in malignant melanomaDNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.Cell-free DNA as a diagnostic marker for cancer: current insightsPharmacologic biomarkers in the development of stratified cancer medicine.The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasmaDevelopment of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenomaLiquid biopsy: monitoring cancer-genetics in the blood.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathologyBRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceExome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary DiseaseCirculating Cell-Free Tumour DNA in the Management of Cancer.SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.Prognostic molecular biomarkers for cutaneous malignant melanomaTesting for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Functional RET G691S polymorphism in cutaneous malignant melanoma.The Pursuit of Noninvasive Diagnosis of Lung Cancer.Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.New approach to cancer therapy based on a molecularly defined cancer classification.Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patientsMutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs.Liquid Biopsies in Oncology and the Current Regulatory Landscape.Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.Liquid biopsy in gastrointestinal stromal tumors: a novel approach.Comparative Aspects of BRAF Mutations in Canine Cancers.Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer.Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
P2860
Q21198860-DDDDE4AC-32CA-485C-8045-0E1BE0A14E00Q26745985-F2303744-5919-46C9-9B18-289902E1A8C0Q26750899-2419E335-D001-489F-8899-1902E481D54FQ26772199-CCF89ED9-9260-4C47-A348-498E3DB84DFFQ26866122-30526D66-5CE5-4882-8F07-CB4ABBEE92C8Q27010159-4DE0B507-7AB1-4C9F-ADC0-7BDC503489B4Q27020946-808079F3-8629-46CB-9005-74C23C54487BQ27336155-25587084-93D5-4E98-929D-97D57128BE00Q28074556-03DEAC10-2E57-4047-BAC8-CBD88C5D661AQ33626476-B17316CB-705B-4BA2-AFCA-270BD55605AFQ33697983-19A60F65-C9C6-4C0B-8D23-6A5BE2498DBBQ33832718-96C53B2B-5C4B-469B-A8A3-C6553E466329Q34254446-6DBC0AF0-8D29-4053-90F5-BCC37B23E4BCQ34356149-061B6F7C-6739-499B-8146-B8CF9DE048D0Q34634536-BBBFDB8C-C0CC-49C8-BC11-2AE1D082940FQ35543094-328D9F76-0568-46FE-BA63-4D350BF92E6CQ35607456-25832E47-6738-44D7-A9F9-BABE492DF28FQ35758472-961F98F6-E3FC-4E82-A7CE-92EA71193E43Q35814162-DCACBC2C-D7CD-4421-9270-C0432538B155Q35839745-49DF4006-D996-41FC-B1F2-E84B48902409Q36073981-0A1A0DCB-3EBE-4882-9F34-719BAF7059C4Q36430821-E3FE50DE-300A-44F7-B14E-1975118E3053Q36452245-90F8C348-5F7F-42F5-8E9F-514530E710FCQ36905877-5603B288-9807-4599-BFCE-FC0F05E31B11Q37242412-0ECDA51F-D4F1-4099-B887-12E9857E1211Q37334690-65FFD307-83C9-4436-B95F-16881857EF8CQ37652904-0112E93B-AB45-454D-B7D0-713E7E607C0FQ38152782-CFBDCAAE-2DE6-43A2-A4AE-827EC542425AQ38163931-B7AA3DB0-6592-4E9E-9E7D-CA7F87531462Q38700529-FC2850D5-6B0E-441A-8184-35A52697BC4FQ38714591-51935344-0EA7-4604-AB2B-6FB2B492C35FQ38871132-8AC7B025-C619-4899-B676-A73FA4F5E990Q39292740-1F514D03-4ECA-4317-88F4-9E8A641E44E7Q39782693-ADE22FF8-EDF2-48AF-A43F-879497541E5DQ39881143-0D000DFF-966E-4CF7-928A-163CBC7347FDQ40441542-9666EC26-2272-4F52-899A-686BC37108BAQ42560645-412DA893-3BEA-491E-8301-5FA5487D0C6AQ44876415-9A11C3AE-C7A5-48F1-9F5E-5939B81455C2Q47136367-238D90C1-4DA3-469D-AB23-A0933EF2AEF4Q50059462-3061396C-05E2-4070-A329-5D18DF4F35EE
P2860
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Utility of circulating B-RAF D ...... ents receiving biochemotherapy
@en
Utility of circulating B-RAF D ...... nts receiving biochemotherapy.
@nl
type
label
Utility of circulating B-RAF D ...... ents receiving biochemotherapy
@en
Utility of circulating B-RAF D ...... nts receiving biochemotherapy.
@nl
prefLabel
Utility of circulating B-RAF D ...... ents receiving biochemotherapy
@en
Utility of circulating B-RAF D ...... nts receiving biochemotherapy.
@nl
P2093
P2860
P1476
Utility of circulating B-RAF D ...... ents receiving biochemotherapy
@en
P2093
Christine Kuo
Farin Amersi
He-Jing Wang
Joseph Kim
Masaru Shinozaki
Minoru Kitago
Steven J O'Day
P2860
P304
P356
10.1158/1078-0432.CCR-06-2120
P407
P50
P577
2007-04-01T00:00:00Z